High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AllianceBernstein (NYSE:AB) reported record assets under management and its strongest quarterly sales in five years during the second quarter of 2026, as fixed-income demand, private-market deployments and insurance-related mandates helped the firm return to positive organic growth. Adjusted earnin
ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?
Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.
Prosecutors have declined to charge businesses in a number of recent cases—despite believing that senior employees were involved in wrongdoing.
Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.
Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical Devices, and Emerging Markets.
Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara
Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm r
Abbott (ABT) delivered earnings and revenue surprises of +2.34% and +0.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.
Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.
Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.
A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.
Abbott Laboratories is scheduled to report its second-quarter results in July, and analysts expect a single-digit earnings rise.
About 50 million Americans aren’t getting screened for colon cancer at a time when colon-cancer rates are rising.
The Food and Drug Administration is rudderless. Its commissioner, Marty Makary, is gone. The rise of the Make America Healthy Again movement, with its vaccine skepticism and adversarial stance toward drugmakers, has hung over biotech since Robert F. Kennedy Jr. took over at the Department of Health and Human Services.
(Bloomberg) -- President Donald Trump’s latest financial disclosures show that he made a slew of stock and bond purchases with major American companies in the first quarter of the year totaling in the tens of millions of dollars and possibly more. Most Read from BloombergHormuz Oil Flows Creep Higher as More Supertankers ExitIran’s Kharg Island Oil Jetties Empty Again Yesterday, Satellite ShowsWhat Is The Thucydides Trap and Why Did Xi Raise It With Trump?Xi Tells US CEOs on Trump Visit That Chi
Tandem Diabetes Care (NASDAQ:TNDM) reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product
April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
